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Summary Animals bearing a cachexia-inducing tumour, the MAC16 adenocarcinoma, showed a progres-
sive decrease in blood glucose levels with increasing weight loss, while animals bearing a histologically similar
tumour, the MAC13 adenocarcinoma, showed no change in either body weight or blood glucose levels with
growth of the tumour. The effect of the MAC16 tumour on blood glucose levels appeared to be unrelated to
food intake, glucose consumption by the tumour, or to the production of increased levels of IGF-I and IGF-II
mRNA by the tumour cells. The relationship between the induction of cachexia and alteration in blood
glucose levels remains unknown.
A high rate of glucose consumption under both anaerobic
and aerobic conditions is a characteristic feature of both
experimental (Weber et al., 1961; Weber, 1977) and human
tumours (Nolop et al., 1987). Alterations in glucose
metabolism in tumour cells are associated with an increased
intracellular concentration of glucose, which is tightly
coupled with an over-expression of facilitative glucose trans-
porter genes (Yamamoto et al., 1990), an increased transcrip-
tion of the hexokinase gene (Johansson et al., 1985), as well
as alterations in isoenzyme profiles of the enzymes involved
in glycolysis (Weber et al., 1961). The enhanced glucose
transport is not insulin-dependent, since hypoglycaemia often
develops in both tumour-bearing animals (Bibby et al., 1987)
and cancer patients (Heber et al., 1985) with normal or even
decreased blood insulin levels.
The architecture of solid tumours also plays an important
role in determining the metabolic substrate for energy prod-
uction. Large solid tumours tend to have a poor blood
supply, and consequently become hypoxic, in which case
glucose will become the predominant metabolic substrate,
since the Embden-Meyerhof pathway is the only means of
ATP production in the absence of oxygen.
We have recently reported studies on glucose utilisation by
tumour and host tissues in NMRI mice bearing the MAC16
colon adenocarcinoma, which is capable of inducing cachexia
in recipient animals (Mulligan & Tisdale, 1991). Glucose
consumption by the tumour was second only to brain and
the increased demand for glucose was met by a decrease in
glucose utilisation by host organs and in particular the brain.
This study further investigates changes in blood glucose
levels and the possible role of insulin-like growth factors
(IGF) in the MAC16 model. Since antibodies to both mouse
IGFI and IGFII were not readily available, we have chosen
to measure their production in the MAC16 tumour
indirectly, through the study of gene expression.
Materials and methods
Pure strain NMRI mice were bred in our own colony and
were fed on a rat and mouse breeding diet (Pilsbury, Birmin-
gham, UK) and water ad libitum. Fragments (1 x 2 mm) of
either the MAC16 or MAC13 tumour were implanted into
the flank of male NMRI mice (starting weight 28 g) by
means of a trocar as described (Bibby et al., 1987). Animals
were transferred to individual cages and body weight, food
and water intake were recorded daily. Blood glucose was
monitored on approximately 100 Il of blood obtained from
the tail vein using the o-toluidine reagent kit (Sigma
Chemical Co., Poole, Dorset, UK).
Analysis ofRNA
Total RNA was isolated by the lithium chloride precipitation
method described by Cathala et al. (1983) from either
MAC16 or MAC13 cells (107) grown in RPMI 1640 medium
with 10% foetal calf serum or from solid tumour (1 g)
immediately after removal from the animal. The concentra-
tion of RNA was determined by absorption at 260 nm and
the purity was checked by running a small aliquot under
denaturing conditions through a formaldehyde agarose gel.
Poly (A)' RNA was purified from total RNA by a single
fractionation over oligo (dT)-cellulose (Maniatis et al., 1989).
Poly(A)+ and total RNA were electrophoresed in 1.2%
agarose containing formaldehyde and transferred by capillary
action to a solid phase-Zetaprobe nylon membrane as des-
cribed (Maniatis et al., 1989).
Probes
The human IGFII 1.7 kb EcoRl fragment of Hep 5, pUC 8
and the human IGFI 1.0 kb Pst 1 fragment of phIGF-I (pKT
218) were kindly supplied by Dr P.N. Schofield, Cambridge
University, UK. Mouse IGFI 0.7 kb EcoRl insert in pBR
322 was kindly provided by Dr G Bell, Howard Hughes
Medical Institute, Chicago, USA and mouse actin 1.4 kb Pst
1 fragment in pAM 91 from Dr G. Cramb, University of St
Andrews, UK. An oligonucleotide probe 30 nucleotides in
length, derived from the published rat IGF-II gene sequence
was synthesised in the Department of Biochemistry, Univer-
sity of Leicester, UK. The antisense oligonucleotide sequence
used for rat IGFII is 5'CTGATGGTTGCTGGACATCTC-
CGAAGAGGC3'. The cDNA probes were labelled with 32p
using a multiprime kit (Amersham International, Amersham,
UK), while the oligonucleotide probe was end-labelled with
32p using polynucleotide kinase (Maniatis et al., 1989). Con-
ditions of low stringency (1 M NaCI, 50% formamide at 42'C
for 12 h) were chosen for hybridisation and initial post hyb-
ridisation to obtain informaton on the size and number of
IGFI and IGFII mRNA transcripts in MAC16 cells followed
by a higher stringency (0.1 x SSC, p.1% SDS at 65°C for
20 min) wash. Autoradiography was performed with an
intensifying screen and the membrane was exposed to
.Hyperfilm MP (Amersham, UK at - 70°C overnight).
Results
Male NMRI mice transplanted with the MAC16 adenocar-
cinoma showed a progressive decrease in body weight from
day 10 after transplantation when the tumour became pal-
pable (Figure 1). Blood glucose levels were reduced by the
transplantation procedure, but had recovered to normal
values within the 10 day period. Thereafter blood glucose
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Figure 1 Changes in body weight (0) and blood glucose concentration (U) in male NMRI mice
adenocarcinoma. The tumour volume on day 15 when blood glucose levels were decreased was 170mm3.
mean ± SEM for five mice.
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Figure 2 Body weight (0) and blood glucose concentration (-) in male NMRI mice bearing the MAC13 adenocarcinoma. Values
are shown as mean ± SEM for eight mice.
declined in proportion to weight loss (Figure 1) with a
minimum value when weight loss was approximately 20%
and the tumour volume was 680 mm3. In contrast, animals
bearing the MAC13 tumour, which did not induce weight
loss, showed no decrease in blood glucose levels during the
course of the experiment (Figure 2). In order to reduce the
fluctuation in food and water intake due to the stress induced
by blood sampling, a separate experiment was performed
where blood glucose was only measured at the start
(123 ± 3.2 mg 100 ml1') and end (100 ± 3.6 mg 100 ml1') of
the experiment. In this case food and water intake remained
at control levels with little fluctuation, even after the onset of
weight loss (Figure 3). In some cases food intake dropped
when the weight loss approached 30%.
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of progressive weight loss (E) on food a, and water b, intake in male NMRI mice bearing the MAC16
In order to try to determine the mechanism responsible for
the decrease in blood glucose in animals bearing the MAC16
tumour, the expression of the genes for IGFI and IGFII were
assessed in both the MAC16 and MAC13 tumour types.
Poly(A)+RNA was purified from total RNA through oligo
dT-cellulose columns and the yield was approximately 1.3%.
Formaldehyde gel electrophoresis showed that the RNA was
intact. Using RNA from the liver of newborn rats as a
positive control for expression of IGFII, a strong signal was
obtained using a rat oligonucleotide probe (Figure 4),
indicating the presence of two IGFII transcripts of 4.7 and
3.5 kb. No IGFII transcripts were detected, however, in
either the MAC16 or MACL3 cell line using either the rat or
human IGFII probes and no transcripts were detected in
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either cell line using a mouse or human IGFI cDNA probe.
Poly(A)+RNA was also extracted from MAC16 tumours
removed from eight mice, all of which were hypoglycaemic.
Total RNA extracted appeared intact, as shown by for-
maldehyde gel electrophoresis. Again no transcripts for
IGFII were detected in any of the samples of poly(A)+RNA
from the cachectic, hypoglycaemic mice (Figure 5). Thus it
was concluded that the genes for IGFI and IGFII were not
expressed by the MAC16 or MAC13 cells either in vitro or in
vivo.
Discussion
Tumour associated hypoglycaemia is often seen in cancer
patients with large mesenchymal tumours (Kahn, 1980) and
it has been suggested that since hypoglycaemia usually occurs
when the tumour has reached a large size, the high glycolytic
activity of the tumour tissue might lead to a depjletion of
circulating glucose. However, in the case of the MAC16
adenocarcinoma, hypoglycaemia occurs when the tumour
mass is small, suggesting the production by the tumour of
peptides that mimic the effect of insulin. The most obvious
candidates are the insulin-like growth factors, Which are sin-
gle chain polypeptides evolutionary related to insulin.
Elevated levels of IGF mRNA have been found in a number
of tumour types of mesenchymal origin, associated with
hypoglycaemia (Tricoli et al., 1986; Hoppener et al., 1988;
Schofield et al., 1989).
Animals bearing the MAC16 adenocarcinoma show a pro-
gressive decrease in blood glucose levels as weight loss inc-
reases. The decrease in blood glucose level appears to be
a
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specific to the cachectic state, since animals bearing a closely
related tumour, the MAC13 adenocarcinoma, which does not
produce weight loss, show normal levels of blood glucose
despite progressive tumour growth. Low blood glucose levels
would be expected to trigger glucose-generating pathways
such as gluconeogenesis from sources such as lactate, alanine
and glycerol. The plasma levels of both lactate (Bibby et al.,
1987) and alanine (Beck & Tisdale, 1989) have been found to
be decreased in animals bearing the MAC16 tumour, while
urinary nitrogen levels have been found to be increased. This
increased use of amino acids for gluconeogenesis would lead
to catabolism of muscle proteins as observed with this
tumour model (Beck & Tisdale, 1987).
The difference in ability to maintain blood glucose levels in
animals bearing the MAC16 and MAC13 tumours appears to
be unrelated either to food intake or the glucose consump-
tion by the tumour cells, since glucose utilisation by the
MAC13 tumour has been shown to be significantly higher
than by the MAC16 tumour (Mulligan & Tisdale, 1991).
McFadzean and Yeung (1969) were able to separate two
types of hypoglycaemia in patients with hepatocellular car-
cinoma. Those with type A hypoglycaemia developed mild
reductions in plasma glucose associated with cachexia, while
those with type B hypoglycaemia demonstrated marked
decreases in glucose levels in patients in whom cachexia was
not a feature. The decreases in blood glucose in the latter
group of patients appear to arise from an increased IGFII
high molecular weight production by the tumour cells
(Shapiro et al., 1990). In the present study we have been
unable to demonstrate increased levels of IGFI or IGFII
mRNA in the MAC16 tumour either in vitro or in vivo
although failure to detect increased gene transcription does
b c
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Figure 4 Northern blot analysis of tumour RNA from cells in tissue culture. a, 20 tg of total (lane 1, 3 and 5) or poly(A)+RNA
(lane 2, 4 and 6) from newborn rat liver (lane 1 and 2), MAC16 (lane 3 and 4) and MAC13 (lane 5 and 6) were electrophoresed on
a 1.2% agarose denaturing gel, blotted to Zetaprobe nylon membrane and probed with a 30 nucleotide probe derived from rat
IGFII gene sequence. b/c, 20ttg of total RNA from newborn rat liver (lane 1) or MAC16 (lanes 2 to 5) probed with mouse IGFI
coding sequence b, or mouse actin c. Expression of IGFII should be detectable using much lower concentrations (2.2jLg) of total
RNA (Brown et al., 1986). Similar results to those in b, were obtained using mRNA from MAC16 and MAC13 tumours to detect
expression of IGFI (results not shown).CACHEXIA ASSOCIATED HYPOGLYCAEMIA 819
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Figure 5 Northern blot analysis ofpoly(A)'RNA from newborn
rat liver (RL) or solid MAC16 tumour probed with a rat IGFII
coding sequence. The blood glucose levels (mg 100 ml-') in the
individual mice were B, 112; B2 116; B5 113; B6 92; B7 113; C2
113; C8 120; and C6 151.
not necessarily mean that there is no change in protein
production, since the protein produced could have a longer
half-life, perhaps by association with a binding protein. It is
unlikely that blood glucose levels could be affected by
canonical IGFs, since in order to produce direct interaction
with the insulin receptor, they would have to be present at
enormously high free concentrations. More likely is an
indirect effect on free endogenous concentrations brought
about by the synthesis of large molecular weight forms of
IGFII (Shapiro et al., 1990), which are associated with a
profound disturbance of the serum IGF binding protein
levels. Previous studies have also shown a decreased plasma
insulin level, which may be a response to the falling blood
glucose (Bibby et al., 1987).
Thus the mechanism for the decrease in blood glucose
accompanying weight loss in the MAC16 tumour model
remains unknown. A possible candidate is a substance
immunochemically cross-reactive with insulin (SICRI), which
has been shown to be produced by murine B16 melanoma
cells in vivo (Vuk-Pavlovic et al., 1986). Increased levels of
SICRI were correlated with decreased blood glucose concent-
rations by stimulating glucose uptake by adipose tissue. The
coincidence of a negative nitrogen balance with hypog-
lycaemia is not consistent with the simple overproduction of
IGFs and the data supports this hypothesis. The results
presented here indicate the need for a new candidate
molecule for the causation of the hypoglycaemic/cachectic
state as mimicked in this model system.
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